EyePoint Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
EyePoint Pharmaceuticals has a total shareholder equity of $266.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $355.2M and $88.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$331.05m |
| Equity | US$266.32m |
| Total liabilities | US$88.86m |
| Total assets | US$355.18m |
Recent financial health updates
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16
Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Recent updates
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01EyePoint Pharmaceuticals reports prelim Q4 revenue; strong FY21 product outlook
Jan 11Ocumension Therapeutics invests $15.7M in EyePoint Pharma
Jan 04Financial Position Analysis
Short Term Liabilities: EYPT's short term assets ($344.8M) exceed its short term liabilities ($63.3M).
Long Term Liabilities: EYPT's short term assets ($344.8M) exceed its long term liabilities ($25.6M).
Debt to Equity History and Analysis
Debt Level: EYPT is debt free.
Reducing Debt: EYPT has no debt compared to 5 years ago when its debt to equity ratio was 46.8%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EYPT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EYPT has sufficient cash runway for 2.9 years if free cash flow continues to grow at historical rates of 1.9% each year.